GLPwatch
Wegovy for Polycystic ovary syndrome
semaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCWegovy (semaglutide) is not FDA-approved for polycystic ovary syndrome, and any use for this condition is off-label or investigational. A meta-analysis evaluated the safety profile of semaglutide but did not address its use for polycystic ovary syndrome.
AI summary of the sources below.
| Drug | Wegovy (semaglutide) |
|---|---|
| Condition | Polycystic ovary syndrome |
| Approval status | Investigational / off-label |
| Research papers | 19 |
Wegovy is not FDA-approved for polycystic ovary syndrome; the research below reflects investigational or off-label study only.
Research on semaglutide for polycystic ovary syndrome (19)
- Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity.
- Semaglutide Alleviates Ovary Inflammation via the AMPK/SIRT1/NF‑κB Signaling Pathway in Polycystic Ovary Syndrome Mice.
- Effects of Glucagon-Like Peptide-1 Receptor Agonists on Gut Microbiota in Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome Mice: Compared Evaluation of Liraglutide and Semaglutide Intervention.
- The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study.
- A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data.
- Evaluating the safety profile of semaglutide: an updated meta-analysis.
- Comparative effectiveness of semaglutide <i>versus</i> liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.
- Semaglutide and social media: implications for young women with polycystic ovarian syndrome.
- Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial.
- Semaglutide Alleviates Ovarian Oxidative Stress and Autophagy via the PI3K/AKT/mTOR Pathway in Mice with Polycystic Ovary Syndrome.
- Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study.
- An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review.
- Meta-analysis of the effects of semaglutide on body mass index (BMI) and blood lipid levels in polycystic ovary syndrome patients.
- Semaglutide: A New Medical Swiss Army Knife?
- Semaglutide and human reproduction: caution at the intersection of energy balance, ovarian function, and follicular development.
- Semaglutide and GLP-1 Agonists: Forensic and Medicolegal Implications.
- Comparative Gynecological Safety of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide vs. the GLP-1 Receptor Agonist Semaglutide: A Real-World Pharmacovigilance Analysis (2022-2025).
- Semaglutide alleviates ovarian ferroptosis in polycystic ovary syndrome and is associated with reduced GPX4 promoter hypermethylation.
- Semaglutide and Tirzepatide for the Treatment of Obesity and Weight-Related Comorbidities: A Narrative Review.